AMGN Amgen, Inc.

203.961.07 (+0.53%)
IEX real time price: 1:32:55 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$166.30-$211.90
Volume
627,147
Avg Volume
2,451,447
Dividend TTM
$5.54 (2.73%)
Ex-Dividend Date
2019-08-14

Valuation

Market Cap
$122.31B
Enterprise Value (EV)
$126.30B
PE Ratio
16.05
EV/EBITDA
10.29
Price/Sales
5.12
Price/Book
9.73
PEG Ratio
4.36

Financials

Revenue
$23.77B
Gross Profit
$19.67B
EBITDA
$12.27B
EPS, ttm
$12.71
Profit Margin
35.32%
Revenue/Employee
$1.11M
Next Earnings Date
10/29/2019 (14 days)
Debt to Equity
271%
Debt
$33.29B
Cash
$29.30B
Net Debt
$3.99B

Performance

Beta
0.79
200 Day Moving Avg
$187.81
50 Day Moving Avg
$198.46
52 Week Change
3.73%
YTD Change
6.25%
1 Month Change
4.54%
3 Month Change
15.20%
6 Month Change
6.11%
1 Year Change
3.73%
2 Year Change
11.54%
5 Year Change
55.00%

Share Count

Shares Outstanding
599.7M
Float
598.4M
Restricted Shares
1.3M
Restricted Shares, %
0.21%

Amgen, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Robert A. Bradway

Website: http://www.amgen.com

Description: Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Employees: 21,500